SB-030

Overview: 

Novel therapeutic that is intended to mimic naturally occurring proteoglycans, macromolecules native to the ECM that can provide healing and protective effects in blood vessels. SB-030 is delivered locally, one time during a vascular procedure, and binds to injured aspects of the vessel.  In doing so, SB-030 aims to accelerate healing, reduce acute ECM-mediated inflammation and reduce neointimal hyperplasia. 

Status: 

Purdue Faculty: 

Dr. Alyssa Panitch formerly of Purdue, now of UC Davis

Clinical Trial Information: 

Phase 2 Trial - Angioplasty + SBCV vs. Angioplasty Alone for Femoropopliteal Artery Stenosis

Development Partner: 

Symic Biomedical

Research Articles: 

The inhibition of platelet adhesion and activation on collagen during balloon angioplasty by collagen-binding peptidoglycans

Decorin mimic promotes endothelial cell health in endothelial monolayers and endothelial–smooth muscle co-cultures